About UmanDiagnostics
UmanDiagnostics is a company based in Umea (Sweden) founded in 2006 was acquired by Quanterix in June 2019. UmanDiagnostics offers products and services including NF-Light™ Serum ELISA assay, NF-Light™ CSF ELISA assays, and anti-NF-Light Antibodies. UmanDiagnostics operates in a competitive market with competitors including Cytox, ADx NeuroSciences, Amprion, PeopleBio R&D and Durin Technologies, among others.
- Headquarter Umea, Sweden
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Umandiagnostics Ab
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of UmanDiagnostics
UmanDiagnostics offers a comprehensive portfolio of products and services, including NF-Light™ Serum ELISA assay, NF-Light™ CSF ELISA assays, and anti-NF-Light Antibodies.
Quantifies Neurofilament light in serum for neurological injury detection.
Measures NF-L in CSF samples to detect neuronal damage.
Provides monoclonal antibodies for NF-L research applications.
Funding Insights of UmanDiagnostics
Detailed funding history for UmanDiagnostics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in UmanDiagnostics
UmanDiagnostics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Quanterix.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Assay kits for ultra-sensitive biomarker detection are developed.
|
Locked | Locked | Locked |
Investor details for UmanDiagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by UmanDiagnostics
Investment portfolio details for UmanDiagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - UmanDiagnostics
Detailed financials for UmanDiagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Umandiagnostics Comparisons
Peer comparison for UmanDiagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of UmanDiagnostics
UmanDiagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytox, ADx NeuroSciences, Amprion, PeopleBio R&D and Durin Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Prognostic tests for assessing dementia risk are developed.
|
|
| Locked | Locked | Locked |
Biomarker assays for neurodegenerative diseases are developed using custom antibodies.
|
|
| Locked | Locked | Locked |
Assay technology for misfolded proteins in neurodegenerative disorders is developed.
|
|
| Locked | Locked | Locked |
Immunoassays are developed for early detection of neurodegenerative diseases.
|
|
| Locked | Locked | Locked |
Developer of the diagnostic test for neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Develops biomarkers and diagnostic tests for amyloid-related diseases.
|
Detailed competitors of UmanDiagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Umandiagnostics
Complete news archive for UmanDiagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UmanDiagnostics
UmanDiagnostics was founded in 2006.
UmanDiagnostics is headquartered in Umea, Sweden.
UmanDiagnostics was founded in 2006 in Umea, Sweden, within the biotechnology sector focused on neurological diagnostics. Tools for early detection, treatment efficacy measurement, and disease progression monitoring are developed and marketed, with emphasis on white matter disorders such as multiple sclerosis and amyotrophic lateral sclerosis. The primary product, NF-light, is an ELISA assay enabling neurofilament light quantification in cerebrospinal fluid within three hours.
UmanDiagnostics's top competitors include Amprion, ADx NeuroSciences and PeopleBio R&D.
UmanDiagnostics offers NF-Light™ Serum ELISA assay, NF-Light™ CSF ELISA assays, and anti-NF-Light Antibodies.
UmanDiagnostics has 1 investor. Key investors include Quanterix.